Our Mission
The National Bleeding Disorders Foundation (NBDF) Nevada Chapter is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research.
Our Mission ... In Action
-
We provide year-round events and fundraisers to spread awareness, educate, and generate crucial resources in support of our mission. Hope to see you at our next event!
-
We fight to protect access to quality healthcare and treatments we need to live healthy lives, but we can't do it without your voice. Discover how you and your family can make a big difference by joining our advocacy efforts.
-
We provide mission-focused experiences through education, support, community connections, and fun for those affected by bleeding disorders.
News & Events
NBDF recently learned that Novo Nordisk now has 3,000 IU vial size of Rebinyn® back in stock. Rebinyn is the company's recombinant factor IX extended half-life therapy for the treatment of hemophilia B. It is indicated for the on-demand treatment and control of bleeding episodes and the management of bleeding around surgery. It is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes.
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for IXINITY® (Medexus), a recombinant factor replacement therapy to treat patients with hemophilia B.
The new approval expands the product indication to include the on-demand, prophylactic, and perioperative treatment of children under 12 years of age. The previous indication was limited to adults and older children more than 12 years of age.
For Immediate Release
CONTACT:
Carrie Strehlau and Kyla Clark
National Bleeding Disorders Foundation
212-382-3773
kclark@hemophilia.org%C2%A0" title="Email for Kyla Clark">kclark@hemophilia.org
National Bleeding Disorders Foundation Celebrates Five Years of Community Voices in Research